MaveriX Oncology develops conditionally activated small molecule therapeutics and next-generation targeted-targeted antibody-drug conjugates (TTADCs) to enhance the safety and efficacy of treatments for solid tumors. The company aims to improve patient outcomes by effectively targeting both primary and metastatic cancer, addressing the limitations of traditional chemotherapy and immunotherapy.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional chemotherapy and immunotherapy for solid tumors often lack sufficient tumor specificity, leading to systemic toxicities and limited efficacy, especially in metastatic settings. The tumor microenvironment can also suppress immune responses, hindering effective treatment.
Solution
MaveriX Oncology is developing conditionally activated small molecule therapeutics (CA-SMDCs) and next-generation targeted-targeted antibody-drug conjugates (TTADCs) designed to enhance the safety and efficacy of cancer treatments. The company's IMPACT-2X technology utilizes hydroxylase-releasable masking to generate tumor-specific CA-SMDCs, which are activated by enzymes overexpressed in solid tumors and the tumor immune microenvironment. This approach aims to selectively target both primary and metastatic cancer cells while sparing healthy tissue, overcoming resistance mechanisms and improving patient outcomes. MaveriX's modular CA-SMDC design combines a target-selective molecular mask with a hydroxylase-cleavable linker conjugated to a chosen drug or payload, enabling a multi-target, multi-asset platform. The company is also developing TTADCs to further increase targeting precision and improve the therapeutic index of antibody-drug conjugates.
Target Audience
MaveriX Oncology's primary target audience includes patients with solid tumors, particularly those with metastatic disease, as well as oncologists and researchers seeking more effective and targeted cancer therapies.
Features
- Conditionally Activated Small Molecule Drug Conjugates (CA-SMDCs) that are activated by tumor-associated hydroxylases
- IMPACT-2X technology for generating tumor-specific CA-SMDCs
- Next-generation Targeted-Targeted Antibody-Drug Conjugates (TTADCs) for increased targeting and safety
- PROXACT molecular mask for target selectivity
- Hydroxylase-cleavable linker technology for controlled drug release
- AI-assisted CA-SMDC design combining high throughput and virtual screening (HTS/ HTVS) with AI-Machine Learning algorithms
- Pipeline includes programs targeting multiple solid tumors, including metastatic cancers
- Focus on monotherapy activity with potential for combination therapy, particularly in immunogenically cold tumors